WO1999024596A1 - Expression plasmids for multiepitope nucleic acid-based vaccines - Google Patents
Expression plasmids for multiepitope nucleic acid-based vaccines Download PDFInfo
- Publication number
- WO1999024596A1 WO1999024596A1 PCT/US1998/023745 US9823745W WO9924596A1 WO 1999024596 A1 WO1999024596 A1 WO 1999024596A1 US 9823745 W US9823745 W US 9823745W WO 9924596 A1 WO9924596 A1 WO 9924596A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epitopes
- plasmid
- nucleic acid
- expression
- sequence
- Prior art date
Links
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title abstract description 13
- 239000013613 expression plasmid Substances 0.000 title description 19
- 239000013612 plasmid Substances 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 8
- 230000028993 immune response Effects 0.000 claims abstract description 8
- 230000002068 genetic effect Effects 0.000 claims abstract description 7
- 238000002649 immunization Methods 0.000 claims abstract description 7
- 230000003053 immunization Effects 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 230000008685 targeting Effects 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 11
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 10
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 9
- 230000006337 proteolytic cleavage Effects 0.000 claims description 7
- 238000012384 transportation and delivery Methods 0.000 claims description 7
- 108010068086 Polyubiquitin Proteins 0.000 claims description 6
- 102100037935 Polyubiquitin-C Human genes 0.000 claims description 6
- 230000002132 lysosomal effect Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 230000003190 augmentative effect Effects 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 244000052769 pathogen Species 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000036755 cellular response Effects 0.000 abstract description 2
- 230000008348 humoral response Effects 0.000 abstract description 2
- 230000001976 improved effect Effects 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 102000035195 Peptidases Human genes 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 15
- 108020005067 RNA Splice Sites Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 235000019833 protease Nutrition 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 108091034057 RNA (poly(A)) Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 5
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000005220 cytoplasmic tail Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000007398 protein translocation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 229960003248 mifepristone Drugs 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000940874 Homo sapiens Loricrin Proteins 0.000 description 1
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 101100484217 Rattus norvegicus Slc14a1 gene Proteins 0.000 description 1
- 230000021194 SRP-dependent cotranslational protein targeting to membrane Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010080502 preprolactin Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Definitions
- the invention relates generally to gene therapy, in particular, the invention relates in part to improved plasmids and methods for nucleic acid based vaccines.
- Plasmids are an essential element in genetic engineering and gene therapy. Plasmids are circular DNA molecules that can be introduced into bacterial cells by transformation which replicate autonomously in the cell. Plasmids allow for the amplification of cloned DNA. Some plasmids are present in 20 to 50 copies during cell growth, and after the arrest of protein synthesis, as many as 1000 copies per cell of a plasmid can be generated. (Suzuki et al., Genetic Analysis, p. 404, (1989).)
- Plasmid design and construction utilizes several key factors.
- plasmid replication origins determine plasmid copy number, which affects production yields. Plasmids that replicate to higher copy number can increase plasmid yield from a given volume of culture, but excessive copy number can be deleterious to the bacteria and lead to undesirable effects (Fitzwater, et al . , EMBO J. 7:3289-3297
- genes that code for antibiotic resistance phenotype are included on the plasmid and antibiotics are added to kill or inhibit plasmid-free cells.
- Most general purpose cloning vectors contain ampicillin resistance ( ⁇ -lactamase, or bla) genes. Use of ampicillin can be problematic because of the potential for residual antibiotic in the purified DNA, which can cause an allergic reaction in a treated patient.
- ⁇ -lactam antibiotics are clinically important for disease treatment. When plasmids containing antibiotic resistance genes are used, the potential exists for the transfer of antibiotic resistance genes to a potential pathogen.
- neo gene which is derived from the bacterial transposon Tn5.
- the neo gene encodes resistance to kanamycin and neomycin (Smith, Vaccine 12:1515-1519 (1994)).
- This gene has been used in a number of gene therapy studies, including several human clinical trials (Recombinant DNA Advisory Committee Data Management Report, December, 1994, Human Gene Therapy 6:535-548). Due to the mechanism by which resistance is imparted, residual antibiotic and transmission of the gene to potential pathogens may be less of a problem than for ⁇ -lactams.
- plasmid vectors have also been shown to affect transfection and expression in eukaryotic cells. Certain plasmid sequences have been shown to reduce expression of eukaryotic genes in eukaryotic cells when carried in cis (Peterson, et al . , Mol . Cell . Biol . 7:1563-1567 (1987); Yoder and Ganesan, Mol . Cell . Biol . 3:956-959 (1983); Lusky and Botchan, Nature 293:79-81 (1981); and Leite, et al . , Gene 82:351-356 (1989) ) .
- Plasmid sequences also have been shown to fortuitously contain binding sites for transcriptional control proteins (Ghersa, et al . , Gene 151:331-332 (1994); Tully and Cidlowski, Biochem. Biophys . Res . Comm . 144:1-10 (1987); and Kushner, et al . , Mol . Endocrinol . 8:405-407 (1994)). This can cause inappropriate levels of gene expression in treated patients.
- nucleic acid vaccines or the use of plasmid encoding antigens, has become an area of intensive research and development in the last half decade. Comprehensive reviews on nucleic acid vaccines have recently been published [M.A.
- the use of epitopes small immunologically relevant protein sequences that are capable of inducing both cellular and humoral responses that result in a protective or therapeutic immune response against large and complex pathogens, is an attractive and amenable strategy provided by the present invention for incorporation into nucleic acid-based vaccines. If multiple epitopes are expressed in the context of a synthetic gene construct, immunity against many antigenic targets, multiple strain variants or multiple pathogens is possible. This disclosure describes the structures and characteristics of gene expression systems that are capable of expressing multiple epitopes.
- the invention provides a method of genetic immunization comprising the step of presenting multiple epitopes to an organism in need of said immunization.
- the multiple epitopes are presented with one or more augmenting cytokines and/or are presented with a delivery vehicle selected from the group consisting of cationic lipids, delivery peptides, and polymer based deliver systems .
- the invention features a plasmid for expression of multiple epitopes comprising a nucleic acid sequence encoding multiple epitopes, wherein each of said epitopes is capable of creating an immune response.
- the plasmid includes a promoter, a 5' UTR sequence, and a 3' UTR sequence, a nucleic acid sequence encoding polyubiquitin, there are spacers between the nucleic acid regions encoding each of said epitopes, there are proteolytic cleavage sites between each of said epitopes, there are ER targeting signals between each of said epitopes, there are lysosomal and/or endosomal targeting sequences between each of said epitopes.
- the invention provides a multivalent expression system as shown in Figure 8 and selected from the group consisting of two plasmids, two genes, IRES, and alternative splicing and a method of making a plasmid producing the appropriate nucleic acid sequence.
- Figure 1 shows a plasmid for multiple epitopes using a beads on a string approach.
- Figure 2 shows a plasmid for multiple epitopes using beads on a string fused to polyubiquitin.
- Figure 3 shows a plasmid for multiple epitopes using beads on a string with spacers between epitopes .
- Figure 4 shows a plasmid for multiple epitopes using beads on a string with proteolytic cleavage sites between epitopes.
- Figure 5 shows a plasmid for beads on a string epitopes with ER targeting sequences.
- Figure 6 shows a plasmid for multiple epitopes with ER targeting sequences.
- Figure 7 shows a plasmid for multiple epitopes with lysosomal/endosomal targeting sequences.
- Figure 8 shows types of multivalent expression systems.
- Figure 9 shows a DNA vaccine expression plasmid with two genes .
- Figure 10 shows a design of a drug-controlled DNA vaccine expression plasmid.
- the multiple epitopes are directly linked to each other. No spacer sequences between the epitopes are included.
- the epitope sequences themselves are sufficient for the formation of a functional "pseudo" protein that can be processed into individual peptide epitopes via proteosome cleavage. This concept, i.e. beads-on-a-string, is supported by data that shows full CTL responses to numerous epitopes when they are placed into novel locations within different proteins
- the present invention provides an exemplary expression system for beads-on-a-string as shown below (See Figure 1) :
- Promoter CMV tissue-specific (e.g. APC-specific) , or synthetic promoter
- Intron Synthetic intron that has optimized 5' ss, 3' ss and branch point sequences. Current optimal sequence is IVS 8.
- Initiation codon AUG is placed in the context of the Kozak sequence to ensure optimal initiation of translation.
- epitope String of epitopes, each having a length of 9-10 amino acid residues in length for class I presentation, or >10 amino acid residues for class II presentation. It appears that at least 15 epitopes may be strung together.
- Stop codon For termination of translation. To ensure efficient termination, it is desirable to string two stop codons in tandem. 3' To ensure efficient processing of the
- UTR/poly(A) mRNA an efficient poly (A) signal, such signal as from human growth hormone, is required .
- Ub chains which target the substrates to the 26S proteasome, an abundant cellular protease.
- Ub chain that is fused to the N-terminus of the multiple epitopes that are arranged as beads-on-a-string.
- Expression plasmids with Ub fused to the antigen have been used to achieve class I presentation (Gueguen and Long, Proc . Natl . Acad. Sci . USA 93:14692-97 (1996) ) .
- flanking sequence can profoundly influence the generation of epitopes (Yellenshaw et al . , J. Immunol . , 158:1727-33 (1997); Shastri et al., J. Immunol . , 155:4339-46 (1995); Del-Val et al . , Cell , 66:1145-93 (1991); Eggers et al . , J " . Exp. Med. 182:1865-70 (1995); Niedermann et al .
- Spacers may facilitate the formation of epitopes that induce immunity.
- the spacer sequence should be one that does not conform at all to the rules for class I or II epitope.
- it may be desirable to include a hydrophobic, basic or acidic residue at the C-terminus of the spacer to facilitate cleavage between the spacer and the adjacent epitope.
- the length of the spacer that would be optimal is not known and would have to be determined empirically.
- viruses e.g. retroviruses, flaviviruses
- Cleavage which occurs at specific sites, is catalyzed by host proteinases or by virally encoded proteinases.
- the polyprotein from hepatitis C virus is structured as follows: H2N-C-El-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH.
- Host cell signal peptidases cleave the junctions in the region between C and NS2.
- the viral proteinase (NS2-3 proteinase) cleaves the junction between NS2 and NS3.
- Another viral proteinase cleaves the junctions between NS3 and NS5B .
- One approach is to insert host cell cleavage sites between the epitope sequences. This may be achieved by insertion of the sequences that are located at the junctions between the C-El-E2-p7-NS2 proteins of the hepatitis polyprotein. Other possibilities are to utilize the recognition site for specific cellular proteases.
- a second approach is to insert cleavage sites for the viral proteinase between the epitope sequences. Thus, the site for the sequence recognized by the NS3 proteinase, Asp/Glu-X-X-X-X-Cys/ThrlSer/Ala (Koch and Bartenschlager, Virology, 237:78-88 (1997)), may be inserted.
- the NS3 proteinase must be also encoded by the expression plasmid.
- two transcription units are required, one for the multiepitopes, one for the viral proteinase. See Section V. Multivalent expression plasmids for nucleic acid-based vaccines.
- the classical pathway for antigen presentation in the context of class I involves the partial degradation of antigenic proteins into peptides by the proteasome.
- the peptides are then transported into the endoplasmic reticulum by peptide transporters (TAP-1 and TAP-2) . It is within the lumen of the ER or cis-Golgi that the peptides are loaded into the binding pocket of the MHC class I molecules.
- TAP-1 and TAP-2 peptide transporters
- Ciernik et al . , J. Immunol . 2369-75 (1996) have demonstrated that the immunogenicity of an epitope may be enhanced if the epitope sequence is fused in frame with the adenovirus E3 leader sequence and expressed from a plasmid delivered by particle bombardment.
- ER targeting signals have also been used by Overwijk et al . , Identification of a Kb-restricted Ctl Epitope of Beta- galactosidase : Potential Use in Development of Immunization Protocols for "Self” Antigens, Methods 12: 117-23 (1997) .
- the signal sequence allows the epitope to be targeted to the ER by the standard protein translocation process.
- the N- terminal leader sequence targets the peptide to the ER by first binding, as a nascent sequence, to the 54 kDa subunit of the SRP particle.
- the leader sequence subsequently binds to the b-subunit of the membrane-bound transporter protein, Sec61p. Following entry into the lumen of the ER through a putative channel, a peptidase cleaves the peptide to remove the leader sequence.
- This mechanism is independent of the TAP transporter system. This alternative mechanism may be advantageous if epitope formation by proteasome cleavage, or epitope transport by the TAP system, are limiting steps in antigen presentation.
- a leader sequence preferably needs to be attached to the N-terminus of each epitope. Adding a leader sequence to the multiple epitopes that are arranged as beads-on-a string concept is unlikely to work, since the leader will be attached only to the first epitope sequence. Placing an individual targeting sequence on each of the epitopes that is arranged in a bead-on-a-string assembly is a possibility. However, this strategy will depend on accurate proteolytic cleavage at the N-terminus of the leader sequence and at the C-terminus of the adjoined epitope sequence. A gene expression system that utilizes alternative splicing will yield individual epitopes with their own leader sequences. The peptide epitopes produced by this strategy will not depend on random degradation of a protein precursor.
- the only processing that is required is N-terminal processing that is associated with protein translocation.
- the C-terminal ends of the epitopes are defined by the stop codons that are designed into the system.
- the preprotein products may be incompletely synthesized until protein translocation through the pore into the ER has occurred.
- the prepeptides may be synthesized in their entirety prior to ER translocation. This may expose the prepeptide to the proteasome and transport of proteins that transport epitopes to the ER by the standard pathway.
- Table II describes the genetic elements used in the alternative splicing strategy.
- Element Description ER Signal The N-terminal leader sequence from sequence 5' ss adenovirus E3 or preprolactin Strong 5' splice site, one that exactly matches the consensus sequence . Such a sequence is found in the synthetic intron, IVS8.
- This sequence is derived from the intron synthetic intron, IVS8. It extends from sequence the 3' end of the 5' splice site to the 5' end of the polypyrimidine tract of the 3 'splice site.
- 3' splice sites sites will be designed to be used equally. Thus, their relative strengths need to be mathed. This will be accomplished by introducing purines within the polypyrimidine regions of the splice site sequences.
- Balanced splicing will be achieved by controlling the purine content of the pyrimidine-rich sequences of the 3' splice sites. In general, the greater the purine content, the weaker the splice site.
- one way to design an appropriate alternatively spliced system for epitopes is to model the 3' splice sites of adenoviral late transcripts.
- leader sequence after splicing, the leader sequence must be fused in frame with the peptide sequence of each epitope. Also, by altering the strengths of the 3' splice sites, the relative amounts of the epitopes may be varied. This may important if certain epitopes are more dominant than others . Table III below shows an example of a balanced set at 3' splice sites derived from the adenoviral late transcript.
- TTGTATTCCCCTTAG ⁇ T Ad2 (14149) GTTGTATGTATCCAG ⁇ C Ad2 (16515) GTAACTATTTTGTAG ⁇ A Ad2 (17999) CCATGTCGCCGCCAG ⁇ A Ad2 (18801) ATGTTTTGTTTGAAG ⁇ T Ad2 (21649) TTCCTTCTCCTATAG ⁇ G Ad2 (24094)
- ADRCG ADRCG . Numbers in parentheses indicate the nucleotide position of each 3' splice site. Note the locations of the purines (A or G) that interrupt the polypyrimidine (C or T) region.
- FIG. 7 Promoter / 5' UTR / AUG / ER signal sequence / 5'ss / internal intron sequence / 3'ss-l / epitope-1 / LAMP-1 transmembrane-cytoplasmic tail / stop codon-1 / 3'ss-2 / epitope-2 / LAMP-1 transmbrane-cytoplasmic tail / stop codon-2 / 3' ss-3 / epitope-3 / LAMP-1 transmbrane- cytoplasmic tail / stop codon-3 / 3' UTR/poly(A) signal
- each epitope is preceded by an N-terminal leader sequence (e.g.
- adenovirus E3 adenovirus E3 and followed by the C-terminal endosomal/lysosomal targeting sequence (e.g. the transmembrane and cytoplasmic tail region of LAMP-1) .
- endosomal targeting sequence e.g. the transmembrane and cytoplasmic tail region of LAMP-1 .
- Another sequence that may be employed for endosomal targeting is the cytoplasmic tail of membrane immunoglobulin (Weiser et al . , Science 276:407-9 (1997); Achatz et al., Science 276:409-11 (1997)).
- nucleic acid-based vaccines it may be important to have the capability of expressing multiple gene products.
- expression of multiple intact antigens or multiepitope gene product may enhance the potency of the these vaccines.
- Co-expression of costimulatory proteins, such as IL-2, IL-6, IL-12, GM-CSF, B7.1 or B7.2 have been demonstrated to enhance the immune response to an encoded antigen (Geissler et al . , J. Immunol . 158:1231-1237 (1997), Irvine et al . , (1996); Kim et al., Vaccine 15:879-83 (1997); Okada et al., J. Immunol .
- Co-expression of proteins that facilitate peptide epitope formation such as proteolytic enzymes (e.g. the NS3 protease from hepatitis C (Koch and Bartenshlager, 1997)) or chaperone proteins (e.g. heat shock protein Hsp65 (Wells et al . , Scand. J. Immunol . , 45:605-12 1997)), may also enhance the response.
- proteolytic enzymes e.g. the NS3 protease from hepatitis C (Koch and Bartenshlager, 1997)
- chaperone proteins e.g. heat shock protein Hsp65 (Wells et al . , Scand. J. Immunol . , 45:605-12 1997)
- Hsp65 heat shock protein
- nucleic acid-based vaccine expression plasmid that has two genes is shown in Figure 9.
- the GeneSwitch is a chimeric protein that consists of human progesterone receptor with a modified ligand binding domain, a DNA binding domain from yeast GAL4, and an activator domain from Herpes Simplex VP16.
- a synthetic steroid mifepristone
- the GeneSwitch protein becomes activated (binds the synthetic steroid, presumably dimerizes, and translocates to the nucleus) .
- the activated GeneSwitch then binds to a target sequence (multiple GAL4 binding sites linked to a minimal promoter) and thereby stimulates the transcription of the desired transgene (Wang et al., Proc . Na tl . Acad . Sci . USA 91:8180- 84 (1994); Wang et al . , Nature Biotechnology 15:239-243 (1997a); Wang et al . , Gene Therapy 4:432-41 (1997b)).
- the GeneSwitch may be used to regulate the expression of a plasmid for nucleic acid-based vaccines. It is possible that the timing of expression may influence the immune response. Thus, with a GeneSwitch regulated system, the genes that encode the multiepitopes may be turned on at a defined time after DNA delivery by the administration of the ligand (mifepristone) to the animal. If the expression plasmid persists in vivo for a long enough time, the GeneSwitch system also can be used to provide pulsatile expression of the multiepitope gene products. An example of the design of a system that is regulated by the GeneSwitch is shown in Figure 10.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002309344A CA2309344A1 (en) | 1997-11-12 | 1998-11-09 | Expression plasmids for multiepitope nucleic acid-based vaccines |
EP98957671A EP1030927A1 (en) | 1997-11-12 | 1998-11-09 | Expression plasmids for multiepitope nucleic acid-based vaccines |
AU13872/99A AU1387299A (en) | 1997-11-12 | 1998-11-09 | Expression plasmids for multiepitope nucleic acid-based vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6513497P | 1997-11-12 | 1997-11-12 | |
US60/065,134 | 1997-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999024596A1 true WO1999024596A1 (en) | 1999-05-20 |
Family
ID=22060567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/023745 WO1999024596A1 (en) | 1997-11-12 | 1998-11-09 | Expression plasmids for multiepitope nucleic acid-based vaccines |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1030927A1 (en) |
AU (1) | AU1387299A (en) |
CA (1) | CA2309344A1 (en) |
WO (1) | WO1999024596A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063770A2 (en) * | 2001-11-07 | 2003-08-07 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
WO2004018666A1 (en) * | 2002-08-20 | 2004-03-04 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
EP1733034A2 (en) * | 2004-03-15 | 2006-12-20 | Biogen Idec MA, Inc. | Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
WO2007087851A2 (en) * | 2006-02-01 | 2007-08-09 | Tgcbiomics Gmbh | Method for producing epitomers and their uses on carrier microorganisms |
US7807780B2 (en) * | 2000-07-21 | 2010-10-05 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
US8974774B2 (en) | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9180081B2 (en) | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US11564998B2 (en) | 2012-04-02 | 2023-01-31 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002805A2 (en) * | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
WO1994024870A1 (en) * | 1993-01-20 | 1994-11-10 | Biotransplant, Inc. | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites |
WO1996003144A1 (en) * | 1994-07-27 | 1996-02-08 | The Council Of The Queensland Institute Of Medical Research | Polyepitope vaccines |
DE19514310A1 (en) * | 1995-04-18 | 1996-10-24 | Univ Ludwigs Albert | Vectors for the transfection of eukaryotic cells, their use and thus transfected target cells |
WO1997035021A2 (en) * | 1996-03-20 | 1997-09-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
-
1998
- 1998-11-09 CA CA002309344A patent/CA2309344A1/en not_active Abandoned
- 1998-11-09 WO PCT/US1998/023745 patent/WO1999024596A1/en not_active Application Discontinuation
- 1998-11-09 EP EP98957671A patent/EP1030927A1/en not_active Withdrawn
- 1998-11-09 AU AU13872/99A patent/AU1387299A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002805A2 (en) * | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
WO1994024870A1 (en) * | 1993-01-20 | 1994-11-10 | Biotransplant, Inc. | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites |
WO1996003144A1 (en) * | 1994-07-27 | 1996-02-08 | The Council Of The Queensland Institute Of Medical Research | Polyepitope vaccines |
DE19514310A1 (en) * | 1995-04-18 | 1996-10-24 | Univ Ludwigs Albert | Vectors for the transfection of eukaryotic cells, their use and thus transfected target cells |
WO1997035021A2 (en) * | 1996-03-20 | 1997-09-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US7807780B2 (en) * | 2000-07-21 | 2010-10-05 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
US8252916B2 (en) | 2001-11-07 | 2012-08-28 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
WO2003063770A3 (en) * | 2001-11-07 | 2004-04-01 | Mankind Corp | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
CN1313617C (en) * | 2001-11-07 | 2007-05-02 | 曼康公司 | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
US7232682B2 (en) | 2001-11-07 | 2007-06-19 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
US8637305B2 (en) | 2001-11-07 | 2014-01-28 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
WO2003063770A2 (en) * | 2001-11-07 | 2003-08-07 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
WO2004018666A1 (en) * | 2002-08-20 | 2004-03-04 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens |
US10172877B2 (en) | 2004-03-03 | 2019-01-08 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US8974774B2 (en) | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1733034A4 (en) * | 2004-03-15 | 2010-01-20 | Biogen Idec Inc | Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
JP2007529223A (en) * | 2004-03-15 | 2007-10-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
EP1733034A2 (en) * | 2004-03-15 | 2006-12-20 | Biogen Idec MA, Inc. | Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
US9180081B2 (en) | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US9314416B2 (en) | 2005-03-03 | 2016-04-19 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US10080786B2 (en) | 2005-03-03 | 2018-09-25 | Revance Therapeutics, Inc. | Methods for treating pain by topical application and transdermal delivery of botulinum toxin |
US10744078B2 (en) | 2005-03-03 | 2020-08-18 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
WO2007087851A3 (en) * | 2006-02-01 | 2007-12-21 | Tgcbiomics Gmbh | Method for producing epitomers and their uses on carrier microorganisms |
WO2007087851A2 (en) * | 2006-02-01 | 2007-08-09 | Tgcbiomics Gmbh | Method for producing epitomers and their uses on carrier microorganisms |
US11564998B2 (en) | 2012-04-02 | 2023-01-31 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
Also Published As
Publication number | Publication date |
---|---|
CA2309344A1 (en) | 1999-05-20 |
AU1387299A (en) | 1999-05-31 |
EP1030927A1 (en) | 2000-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dietrich et al. | Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes | |
US9950081B2 (en) | Vectors and methods for genetic immunization | |
Ciernik et al. | Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. | |
JP3881014B2 (en) | Polynucleotide tuberculosis vaccine | |
KR101454842B1 (en) | Improved alphavirus replicons and helper constructs | |
US7744900B2 (en) | Enhancement of the immune response for vaccine and gene therapy applications | |
AU784605B2 (en) | Chimeric immunogenic compositions and nucleic acids encoding them | |
JP4580410B2 (en) | Expression vector capable of inducing improved immune response and method of using this vector | |
JPH02211877A (en) | New recombinant and chimera antibody oriented to human glandular cancer antigen | |
AU2006259041A1 (en) | Agents and methods based on the use of the EDA domain of fibronectin | |
EP1844142B1 (en) | Vectors and methods for genetic immunization | |
EP1435387A1 (en) | The oncolytic microorganisms expressing hsp and uses thereof | |
EP1030927A1 (en) | Expression plasmids for multiepitope nucleic acid-based vaccines | |
ES2834329T3 (en) | Tolerogenic DNA vaccine | |
Khalid et al. | The development of DNA vaccines against SARS-CoV-2 | |
JP2001516210A (en) | Autoregulated apoptosis of inflammatory cells by gene therapy | |
Azevedo et al. | Main features of DNA-based immunization vectors | |
JP2780961B2 (en) | Herpes simplex virus protein and vaccine containing it | |
AU761497B2 (en) | Self-regulated apoptosis of inflammatory cells by gene therapy | |
Davidoff et al. | Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model | |
JP4411213B2 (en) | Vaccines against oncovirus infections such as feline leukemia virus | |
JPH09509562A (en) | Novel protein / polypeptide and cotransfection plasmid and recombinant live carrier thereof | |
WO2002055104A2 (en) | Acne vaccine | |
WO2000028048A1 (en) | Novel plasmids for use in medicine and method of producing same | |
US20220257747A1 (en) | Methods and compositions of astrovirus replicons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 13872/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2309344 Country of ref document: CA Ref country code: CA Ref document number: 2309344 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 519590 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998957671 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998957671 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998957671 Country of ref document: EP |